Gross Profit Summary of Cosmo Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V.'s latest annual gross profit in 2023 was 73.94 Million EUR , down -11.26% from previous year.
Cosmo Pharmaceuticals N.V.'s latest quarterly gross profit in 2024 Q1 was 56.54 Million EUR , up 294.72% from previous quarter.
Cosmo Pharmaceuticals N.V. reported a annual gross profit of 83.32 Million EUR in annual gross profit 2022, up 66.87% from previous year.
Cosmo Pharmaceuticals N.V. reported a annual gross profit of 49.93 Million EUR in annual gross profit 2021, down -1.13% from previous year.
Cosmo Pharmaceuticals N.V. reported a quarterly gross profit of 56.54 Million EUR for 2024 Q1, up 294.72% from previous quarter.
Cosmo Pharmaceuticals N.V. reported a quarterly gross profit of 12.39 Million EUR for 2023 Q1, down -33.56% from previous quarter.

Annual Gross Profit Chart of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Historical Annual Gross Profit of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Year	Gross Profit	Gross Profit Growth
2023	73.94 Million EUR	-11.26%
2022	83.32 Million EUR	66.87%
2021	49.93 Million EUR	-1.13%
2020	50.5 Million EUR	-5.15%
2019	53.24 Million EUR	0.0%
2018	53.24 Million EUR	-3.39%
2017	55.11 Million EUR	-4.11%
2016	57.47 Million EUR	13.75%
2015	50.53 Million EUR	-25.66%
2014	67.97 Million EUR	47.49%
2013	46.08 Million EUR	-9.85%
2012	51.11 Million EUR	168.81%
2011	19.01 Million EUR	7.3%
2010	17.72 Million EUR	27.41%
2009	13.91 Million EUR	-33.66%
2008	20.97 Million EUR	40.95%
2007	14.87 Million EUR	54.0%
2006	9.66 Million EUR	-1.08%
2005	9.76 Million EUR	42.03%
2004	6.87 Million EUR	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q2	56.54 Million EUR	0.0%
2024 Q1	56.54 Million EUR	294.72%
2023 Q1	12.39 Million EUR	-33.56%
2023 Q2	12.39 Million EUR	0.0%
2023 Q3	14.32 Million EUR	15.57%
2023 Q4	14.32 Million EUR	0.0%
2023 FY	73.94 Million EUR	-11.26%
2022 Q1	12.14 Million EUR	39.01%
2022 FY	83.32 Million EUR	66.87%
2022 Q4	18.65 Million EUR	0.0%
2022 Q3	18.65 Million EUR	53.61%
2022 Q2	12.14 Million EUR	0.0%
2021 Q4	8.73 Million EUR	0.0%
2021 Q3	8.73 Million EUR	19.48%
2021 Q1	7.31 Million EUR	-27.94%
2021 FY	49.93 Million EUR	-1.13%
2021 Q2	7.31 Million EUR	0.0%
2020 Q1	6.51 Million EUR	-51.65%
2020 FY	50.5 Million EUR	-5.15%
2020 Q3	10.14 Million EUR	55.65%
2020 Q4	10.14 Million EUR	0.0%
2020 Q2	6.51 Million EUR	0.0%
2019 Q3	13.48 Million EUR	157.34%
2019 Q2	5.23 Million EUR	0.0%
2019 Q1	5.23 Million EUR	-39.8%
2019 Q4	13.48 Million EUR	0.0%
2019 FY	53.24 Million EUR	0.0%
2018 Q3	8.7 Million EUR	-33.45%
2018 Q1	13.07 Million EUR	7.51%
2018 FY	53.24 Million EUR	-3.39%
2018 Q2	13.07 Million EUR	0.0%
2018 Q4	8.7 Million EUR	0.0%
2017 Q3	12.16 Million EUR	13.67%
2017 Q4	12.16 Million EUR	0.0%
2017 FY	55.11 Million EUR	-4.11%
2017 Q1	10.69 Million EUR	-19.06%
2017 Q2	10.69 Million EUR	0.0%
2016 FY	57.47 Million EUR	13.75%
2016 Q4	13.21 Million EUR	0.0%
2016 Q3	13.21 Million EUR	19.61%
2016 Q2	11.05 Million EUR	0.0%
2016 Q1	11.05 Million EUR	-30.07%
2015 Q2	4.45 Million EUR	0.0%
2015 FY	50.53 Million EUR	-25.66%
2015 Q4	15.8 Million EUR	0.0%
2015 Q1	4.45 Million EUR	-67.06%
2015 Q3	15.8 Million EUR	254.54%
2014 Q2	15.51 Million EUR	0.0%
2014 Q4	13.53 Million EUR	0.0%
2014 Q1	15.51 Million EUR	46.6%
2014 Q3	13.53 Million EUR	-12.8%
2014 FY	67.97 Million EUR	47.49%
2013 FY	46.08 Million EUR	-9.85%
2013 Q4	10.58 Million EUR	0.0%
2013 Q1	8.52 Million EUR	64.04%
2013 Q2	8.52 Million EUR	0.0%
2013 Q3	10.58 Million EUR	24.12%
2012 Q4	5.19 Million EUR	0.0%
2012 Q3	5.19 Million EUR	-59.31%
2012 FY	51.11 Million EUR	168.81%
2012 Q1	12.77 Million EUR	0.0%
2012 Q2	12.77 Million EUR	0.0%
2011 Q3	4.75 Million EUR	0.0%
2011 Q1	4.75 Million EUR	0.0%
2011 Q2	4.75 Million EUR	0.0%
2011 FY	19.01 Million EUR	7.3%
2011 Q4	12.77 Million EUR	168.81%
2010 FY	17.72 Million EUR	27.41%
2010 Q3	4.43 Million EUR	0.0%
2010 Q2	4.43 Million EUR	0.0%
2010 Q1	4.43 Million EUR	0.0%
2010 Q4	4.75 Million EUR	7.3%
2009 Q1	3.47 Million EUR	0.0%
2009 FY	13.91 Million EUR	-33.66%
2009 Q4	4.43 Million EUR	27.41%
2009 Q3	3.47 Million EUR	0.0%
2009 Q2	3.47 Million EUR	0.0%
2008 FY	20.97 Million EUR	40.95%
2008 Q4	3.47 Million EUR	-33.66%
2008 Q2	5.24 Million EUR	0.0%
2008 Q1	5.24 Million EUR	0.0%
2008 Q3	5.24 Million EUR	0.0%
2007 FY	14.87 Million EUR	54.0%
2007 Q4	5.24 Million EUR	40.95%
2007 Q3	3.71 Million EUR	0.0%
2007 Q2	3.71 Million EUR	0.0%
2007 Q1	3.71 Million EUR	0.0%
2006 Q1	2.41 Million EUR	0.0%
2006 Q4	3.71 Million EUR	54.0%
2006 FY	9.66 Million EUR	-1.08%
2006 Q2	2.41 Million EUR	0.0%
2006 Q3	2.41 Million EUR	0.0%
2005 Q2	2.44 Million EUR	0.0%
2005 Q3	2.44 Million EUR	0.0%
2005 Q1	2.44 Million EUR	0.0%
2005 Q4	2.41 Million EUR	-1.08%
2005 FY	9.76 Million EUR	42.03%
2004 Q4	2.44 Million EUR	42.03%
2004 FY	6.87 Million EUR	0.0%
2004 Q1	1.71 Million EUR	0.0%
2004 Q2	1.71 Million EUR	0.0%
2004 Q3	1.71 Million EUR	0.0%
2003 Q4	1.71 Million EUR	0.0%

Peer Gross Profit Comparison of Cosmo Pharmaceuticals N.V.

Name	Gross Profit	Gross Profit Difference
Roche Holding AG	42.89 Billion CHF	99.828%
Roche Holding AG	42.89 Billion CHF	99.828%

Global Stocks Search

Cosmo Pharmaceuticals N.V. (COPN.SW)

Gross Profit Summary of Cosmo Pharmaceuticals N.V.

Annual Gross Profit Chart of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Historical Annual Gross Profit of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Peer Gross Profit Comparison of Cosmo Pharmaceuticals N.V.